The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United St… (NCT06854458) | Clinical Trial Compass
RecruitingNot Applicable
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study
United States1,000 participantsStarted 2025-06-27
Plain-language summary
This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.
Who can participate
Age range35 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. male or female at age 35-85 years,
✓. presence of either of the following sign/symptom that led to a referral to stress cardiac magnetic resonance imaging:
✓. chest pain or anginal equivalent, or
✓. abnormal electrocardiogram with a suspicion of coronary artery disease
✓. Intermediate or high risk of significant coronary disease based on at least 1 of the following conditions:
Exclusion criteria
✕. Acute myocardial infarction within the past 30 days prior to cardiac magnetic resonance imaging
✕. Confirmed diagnosis of any significant non-coronary cardiac conditions below:
✕. any severe-grade valvular heart disease,
✕. left ventricular ejection fraction \<40% from any known non-coronary causes,
✕. infiltrative cardiomyopathy,
What they're measuring
1
Primary composite outcome of major cardiovascular adverse events (MACE)
Timeframe: From cardiac magnetic resonance imaging to the end of follow-up in 24 months